Insmed Incorporated (INSM)
After hours:
| Previous close | 25.66 |
| Open | 26.23 |
| Bid | 25.52 x 300 |
| Ask | 25.60 x 200 |
| Day's range | 25.40 - 26.43 |
| 52-week range | 18.09 - 32.00 |
| Volume | |
| Avg. volume | 1,769,064 |
| Market cap | 3.796B |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.34 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 44.13 |
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 63 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
ZacksInsmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first-quarter 2024 financial results on Thursday, May 9, 2024.
